We have located links that may give you full text access.
Misdiagnosis of leiomyosarcoma after radiofrequency ablation of uterine fibroids.
Journal of Minimally Invasive Gynecology 2018 August 17
BACKGROUND: Minimally invasive therapies to treat symptoms of uterine fibroids can be effective alternatives to major surgery. Such modalities include pharmacologic agents, uterine artery embolization (UAE), MR guided focused ultrasound, and laparoscopic radiofrequency ablation (Acessa procedure). Acessa is being used to treat women with symptomatic fibroids and was approved by the FDA in 2012.
CASE: This case describes a patient who underwent Acessa and subsequently required hysterectomy for refractory symptoms. Pathology of her tumor was initially classified as epithelioid leiomyosarcoma, but on subsequent review was classified as benign.
CONCLUSION: This report highlights the challenges of accurate histologic diagnosis in the setting of using new therapeutic modalities. Clinicians should report such interventions to pathologists at the time of surgery to allow for accurate diagnosis.
CASE: This case describes a patient who underwent Acessa and subsequently required hysterectomy for refractory symptoms. Pathology of her tumor was initially classified as epithelioid leiomyosarcoma, but on subsequent review was classified as benign.
CONCLUSION: This report highlights the challenges of accurate histologic diagnosis in the setting of using new therapeutic modalities. Clinicians should report such interventions to pathologists at the time of surgery to allow for accurate diagnosis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app